Shots:

• The MAA is based on P-III OPTIMUM study assessing Ponesimod (20mg) vs Teriflunomide (14 mg) in patients with RMS
• The P-III OPTIMUM study results: @108wks. 30.5% reduction in ARR; 56% reduction CUALs in the brain; reduction in fatigue symptoms; safety profile is consistent with the previous studies
• Ponesimod is an investigational S1P1 modulator- act by inhibiting S1P activity leading to a reduction in the number of circulating lymphocytes crossing the BBB  

­ Ref: J&J | Image: Janssen